Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17157064 | 0.89 | S1PR1 (0.49) | ESR2S1PR1PTGDR2ESR1TP53 | |
| SCHEMBL4751085 | 0.85 | S1PR1 (0.48) | ESR2S1PR1PTGDR2 | |
| SCHEMBL30199116 | 0.85 | ESR2 (0.56) | ESR2NR1H2S1PR1GPR119CYP4F2 | |
| SCHEMBL30199433 | 0.85 | ESR2 (0.56) | ESR2NR1H2S1PR1GPR119CYP4F2 | |
| SCHEMBL29097892 | 0.85 | ESR2 (0.56) | ESR2NR1H2S1PR1GPR119CYP4F2 | |
| SCHEMBL30199177 | 0.84 | ESR2 (0.53) | ESR2NR1H2S1PR1GPR119CYP4F2 | |
| SCHEMBL29097849 | 0.84 | ESR2 (0.53) | ESR2NR1H2S1PR1GPR119CYP4F2 | |
| SCHEMBL30198885 | 0.82 | ESR2 (0.53) | ESR2NR1H2S1PR1GPR119CYP4F2 | |
| SCHEMBL30199620 | 0.82 | ESR2 (0.53) | ESR2NR1H2S1PR1GPR119CYP4F2 | |
| SCHEMBL29097963 | 0.82 | ESR2 (0.53) | ESR2NR1H2S1PR1GPR119CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644367-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| EP-1644367-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-12-31 | — | — | EP | disclosed |
| US-7462629-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-12-09 | — | — | US | disclosed |
| EP-1644367-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-04-12 | — | — | EP | disclosed |
| US-20050009786-A1 | Immunosuppressant compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-01-13 | — | — | US | disclosed |
| WO-2004113330-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009786-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | ESR2 659/4885NR1H2 1070/4885S1PR1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.